Urogen Pharma (URGN)

Urogen Pharma Stock Price & Analysis


URGN Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.85 - $12.63
Previous Close$8.17
Average Volume (3M)65.94K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$95.91M
Total Debt (Recent Filing)$73.73M
Price to Earnings (P/E)-1.7
Next EarningsMar 16, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-4.83
Shares Outstanding23,090,039
Standard Deviation0.19
10 Day Avg. Volume73,282
30 Day Avg. Volume65,944
Price to Book (P/B)-2.77
Price to Sales (P/S)2.81
Price to Cash Flow (P/CF)71.30
P/FCF Ratio-2.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside203.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1


Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $4.85 and its highest was $12.63 in the past 12 months.
    What is Urogen Pharma’s market cap?
    Currently, no data Available
    When is Urogen Pharma’s upcoming earnings report date?
    Urogen Pharma’s upcoming earnings report date is Mar 16, 2023 which is in 106 days.
      How were Urogen Pharma’s earnings last quarter?
      Urogen Pharma released its earnings results on Nov 10, 2022. The company reported -$1.13 earnings per share for the quarter, beating the consensus estimate of -$1.157 by $0.027.
        Is Urogen Pharma overvalued?
        According to Wall Street analysts Urogen Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Urogen Pharma pay dividends?
          Urogen Pharma does not currently pay dividends.
          What is Urogen Pharma’s EPS estimate?
          Urogen Pharma’s EPS estimate is -$1.05.
            How many shares outstanding does Urogen Pharma have?
            Urogen Pharma has 23,090,038 shares outstanding.
              What happened to Urogen Pharma’s price movement after its last earnings report?
              Urogen Pharma reported an EPS of -$1.13 in its last earnings report, beating expectations of -$1.157. Following the earnings report the stock price went down -16.317%.
                Which hedge fund is a major shareholder of Urogen Pharma?
                Among the largest hedge funds holding Urogen Pharma’s share is Wildcat Capital Management, Llc. It holds Urogen Pharma’s shares valued at 4M.


                  Urogen Pharma Stock Smart Score

                  The Urogen Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Urogen Pharma

                  UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in New York, NY.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Enlivex Therapeutics
                  Collplant Holdings
                  Neoleukin Therapeutics
                  Gamida Cell

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis